TP53 and myelodysplastic syndrome: Another AML patient with MDS-related features (UPN01 from Cohort 6B, Dose level: 0.1 mcg/kg), who had 29% bone marrow blasts, unfavorable cytogenetics (del 5q and monosomy 7) and TP53 mutation, whose disease had previously progressed on Venetoclax + Decitabine therapy, achieved a PR at 31 days and CR at 92 days following APVO436 monotherapy with full hematologic recovery as BOR (Table 1 and Figure S1).